Lineage Cell Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
LCTX$1.04-3.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| NET LOSS | $(63,367) | $(18,582) |
| Other comprehensive loss: | ||
| Foreign currency translation adjustment, net of tax | (1,046) | 189 |
| Unrealized gain on marketable debt securities | 2 | 3 |
| COMPREHENSIVE LOSS | (64,411) | (18,390) |
| Comprehensive (income) loss attributable to noncontrolling interest | (166) | (27) |
| COMPREHENSIVE LOSS ATTRIBUTABLE TO LINEAGE COMMON SHAREHOLDERS | $(64,577) | $(18,417) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.